One Strikeout, One Hit Against Low-Grade Serous Carcinomas
Two MEK inhibitors were tested against recurrent low-grade serous carcinomas of the ovaries, fallopian tubes, or peritoneum, but only one offered clinical benefit over standard care, say researchers. Medscape Medical News …read more